PCRX vs XYL · P/E 174, rev $369.8M vs P/E 27, rev $4.46B
Pacira BioSciences, Inc. (PCRX) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the PCRX and XYL stock pages for the full models.
Not investment advice.